Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
22/06/2026 12:47
BRIEF-Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg) June 22 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
CEMDISIRAN REGULATORY SUBMISSIONS ACCEPTED FOR REVIEW BY FDA AND EMA FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG)
REGENERON PHARMACEUTICALS - EUROPEAN COMMISSION DECISION ON CEMDISIRAN EXPECTED IN SECOND HALF OF 2027
REGENERON PHARMACEUTICALS - PLANS REGULATORY FILING FOR CEMDISIRAN IN JAPAN IN EARLY 2027
REGENERON PHARMACEUTICALS - FDA TO REVIEW CEMDISIRAN NDA UNDER PRIORITY REVIEW WITH TARGET ACTION DATE NOVEMBER 2026
Source text: ID:nGNX5r0zrs
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement